913828-95-2

Upstream product

• 108-95-2 phenol 
• 230623-72-0 (4-bromo-thiophene-2-ylmethoxy)-tert-butyl-dimethylsilane 
• 79757-77-0 (4-bromothiophen-2-yl)methanol 
• 67-36-7 4-phenoxy benzaldehyde 
• 913828-80-5 tert-butyl[(4-ethyl-2-thienyl)methoxy]dimethylsilane 
• 913828-83-8 5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3-ethyl-N'-hydroxythiophene-2-carboximidamide 
• 913828-82-7 5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3-ethylthiophene-2-carbonitrile 
• 1028947-14-9 C₁₄H₂₅NO₂SSi 
• 913828-81-6 5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3-ethylthiophene-2-carboxaldehyde 
• 18791-75-8 4-Bromothiophen-2-aldehyde 

Relevant academic research and scientific papers

Synthesis and evaluation of CS-2100, a potent, orally active and S1P 3- sparing S1P1 agonist

Modulators of sphingosine phosphate receptor-1 (S1P1) have recently been focused as a suppressant of autoimmunity. We have discovered a 4-ethylthiophene-based S1P1 agonist 1-({4-Ethyl-5-[5-(4- phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-t

Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist

S1P3-sparing S1P1 agonists have attracted attention as a suppressant of autoimmunity with reduced side effects. Our synthetic efforts and extensive SAR studies led to the discovery of 10b named CS-2100 with the EC50 value of 4.0 nM for human S1P1 and over 5000-fold selectivity against S1P3. The in vivo immunosuppressive efficacy was evaluated in rats on host versus graft reaction and the ID 50 value was determined at 0.407 mg/kg. The docking studies of CS-2100 with the homology model of S1P1 and S1P3 showed that the ethyl group on the thiophene ring of CS-2100 was sterically hindered by Phe263 in S1P3, not in the case of Leu276 in S1P1. This observation gives an explanation for the excellent S1P3-sparing characteristic of CS-2100.

HETEROCYCLIC COMPOUND

[Object] To provide a novel compound having an excellent immunosuppressive activity with low toxicity or a pharmacological salt thereof. [Means to achieve the object] A compound having general formula (I) shown below or a pharmacologically acceptable salt thereof, or a pharmacologically acceptable prodrug thereof [wherein A represents a carboxyl group, or the like, B represents a hydrogen atom, or the like, V represents a single bond, a methylene group, or the like, n represents an integer of from 0 to 2, W represents a 5- to 7-membered heterocyclic group, or the like, Z represents a group selected from Substituent group A, or the like, and Substituent group A represents the group consisting of a halogen atom, a C1-C6 alkyl group, a C3-C7 cycloalkyl group.